Last updated: February 17, 2026
Product Overview
NDC 00054-4297 corresponds to Humira (adalimumab), a monoclonal antibody used primarily for autoimmune conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis.
Market Size and Competitive Landscape
Humira dominates the biologics segment for autoimmune diseases. Its global revenue reached approximately $21 billion in 2022, according to AbbVie’s financial disclosures [1]. The drug's patent expirations began in 2018 in Europe and in 2023 in the United States, opening markets for biosimilars.
As of 2023, biosimilar competition has increased significantly:
- United States: Several biosimilars approved and launched, including Amgen's Amjevita and Samsung Bioepis's Hadlima.
- Europe: Multiple biosimilars available since 2018 with significant market penetration.
- Market share shift: Biosimilars captured approximately 30% of Humira’s US injectable market by mid-2023.
Pricing Dynamics
- Branded Humira: List price in the U.S. averages $6,000 per month per patient before insurance discounts [2].
- Biosimilars: Introduced at 15-30% discount relative to the brand, with some offerings priced around $4,500–$5,000. Educational and contractual factors influence actual transaction prices.
Price Trends and Projections
- Short-term (2023–2025): Biosimilar penetration is expected to increase, reducing the average price per unit of Humira. Prices are projected to decline by 10-20% as insurers and payers shift toward biosimilar utilization.
- Medium-term (2025–2030): Continued biosimilar adoption could push biologic prices down by up to 30% relative to peak branded levels. Patent expirations will enable more biosolars to enter the market, intensifying price competition.
- Long-term (beyond 2030): Generic-like biosimilar markets may stabilize prices, with possible reductions reaching 50% from peak branded levels. This depends on market acceptance, formularies, and reimbursement policies.
Revenue Impact Estimates
- For AbbVie, Humira’s revenue could decrease by approximately 40-50% in the U.S. market from 2024 onwards due to biosimilar competition.
- Export markets such as Europe, where biosiminiar penetration is more advanced, already show revenue declines of approximately 20% since biosimilar availability.
Strategic Considerations for Stakeholders
- Manufacturers: Focus on biosimilar differentiation, cost reduction, and strategic alliances to capture market share.
- Providers and payers: Shift towards biosimilar utilization to manage costs.
- Investors: Monitor biosimilar launch timelines and market share gains for valuation adjustments.
Concluding Summary
Humira (NDC 00054-4297) remains a leading biologic for autoimmune conditions, but biosimilar competition is significantly eroding its market share and prices. Market penetration will likely intensify, driving prices downward. Long-term revenue impacts and pricing adjustments depend on regulatory, contractual, and formulary strategies.
Key Takeaways
- Humira's global revenue hit $21 billion in 2022.
- Biosimilars launched in the U.S. in 2023 are capturing an increasing share.
- Prices for Humira are expected to decline 10-30% over the next five years.
- Biosimilar competition could reduce revenue by up to 50% by 2030.
- Strategic responses include price negotiations, biosimilar adoption, and innovative formulations.
FAQs
1. When did biosimilar versions of Humira enter the U.S. market?
Biosimilars for Humira gained FDA approval in 2017, with market entry beginning in 2023 after patent expirations.
2. How much have biosimilars impacted Humira’s market share?
By mid-2023, biosimilars captured approximately 30% of the U.S. injectable autoimmune biologic market.
3. What is the typical price difference between Humira and its biosimilars?
Biosimilars are generally priced 15-30% lower than the branded drug.
4. What are the key factors influencing Humira’s future pricing?
Pricing is affected by biosimilar rollout speed, formulary preferences, payer negotiations, and regulatory policies.
5. Will the revenue decline for Humira stabilize?
Yes, once biosimilar markets mature, a stabilization at 50% of peak revenues is possible, contingent on market dynamics and new formulations.
References
[1] AbbVie Financial Report 2022.
[2] IQVIA. 2023 Biologic Pricing Data.
